Aspirin regulation of c-myc and cyclinD1 proteins to overcome tamoxifen resistance in estrogen receptor-positive breast cancer cells

Tamoxifen is still the most commonly used endocrine therapy drug for estrogen receptor (ER)-positive breast cancer patients and has an excellent outcome, but tamoxifen resistance remains a great impediment to successful treatment. Recent studies have prompted an anti-tumor effect of aspirin. Here, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Ran, Liu, Ya-Jing, Cui, Jun-Wei, Yang, Man, Liu, Xiao-Ling, Li, Peng, Wang, Zhan, Zhu, Li-Zhang, Lu, Si-Yi, Zou, Li, Wu, Xiao-Qin, Li, Yu-Xia, Zhou, You, Fang, Zheng-Yu, Wei, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444740/
https://www.ncbi.nlm.nih.gov/pubmed/28415819
http://dx.doi.org/10.18632/oncotarget.16325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444740/
https://www.ncbi.nlm.nih.gov/pubmed/28415819
http://dx.doi.org/10.18632/oncotarget.16325

Ejemplares similares